The global Dyslipidemia Drugs Market, which treat unhealthy or abnormal levels of lipids (fats) in the blood, reached a substantial size of USD 17.36 Billion in 2022. Projections indicate that it is poised for robust growth, with an expected value of USD 28.57 Billion by the year 2032, representing a remarkable compound annual growth rate (CAGR) of 4.8% during the forecast period. This growth can be attributed to several key factors driving the market's expansion. https://www.reportsanddata.com/report-detail/dyslipidemia-drugs-market